Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451016 | 0.81 | MEN1 (0.44) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL18672255 | 0.78 | IDO1 (0.39) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL2202537 | 0.78 | VHL (0.38) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL2237097 | 0.78 | TRPA1 (0.37) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL11941058 | 0.78 | ALDH1A1 (0.43) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL7473813 | 0.78 | CCNB2 (0.35) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL1680897 | 0.78 | HRH3 (0.42) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL25383174 | 0.75 | CCNB2 (0.33) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL8803609 | 0.75 | CA2 (0.45) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL8804519 | 0.75 | TAAR1 (0.43) | KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150165074-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | LANTHEUS MEDICAL IMAGING, INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165074-A1 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF | TNNI3, FABP3, MPI | CCNB2 3602/4885CDK1 2610/4885CCNB1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.